# HERIZON-BTC-01 (NCT04466891)

> A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04466891
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Jazz Pharmaceuticals
- Conditions: HER2-amplified Biliary Tract Cancers
- Interventions: ZW25 (Zanidatamab)
- Enrollment: 87
- Primary outcome: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR)

## Commentary we found

- YouTube: 37
- Podcasts: 36
- X threads: 35
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=herizon-btc-01-nct04466891

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04466891", "email": "<work email>"}; the inbox owner confirms by the emailed link.